Supernus and Indivior Close Merger, Launch Combined CNS Company With 11-Product Portfolio
SUPN is trading near its 52-week low of $37.54 (12% above the low) on elevated volume (3.3× avg).
Summary
Supernus and Indivior closed their merger, creating Supernus, Inc., a combined CNS biopharma with an 11-product portfolio including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO and ZURZUVAE. The deal follows the definitive proxy filed September 11 and the October 15 stockholder approval, and now converts the announced terms into an operating company. Supernus holders received 1.5401 Indivior shares per share; former Indivior holders own about 56.5% of the combined company and former Supernus holders about 43.5%. Indivior stockholders get a one-time $1.0 billion aggregate special dividend, funded with a $650 million Citibank term loan plus existing cash. Jack Khattar stays President and CEO and Tony Kingsley chairs an eight-director board split evenly between the two legacy companies. The stock trades under INDV on November 2 and shifts to SUPN on November 3, 2026, so expect index and ticker-related flows around that transition.
At the time of this announcement, SUPN was trading at $41.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $37.54 to $59.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.